Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Clinical trial evidence shows that abiraterone plus ADT, with prednisolone or prednisone is more effective than placebo plus ADT and ADT alone. Although it has not been directly compared with enzalutamide plus ADT or apalutamide plus ADT, indirect comparisons suggest it is likely to work as well as these combinations, indicating a clear clinical advantage.
Cost effectiveness
A cost comparison indicates that the costs for abiraterone plus ADT are similar to or lower than both enzalutamide plus ADT and apalutamide plus ADT, supporting its cost-effectiveness under common thresholds.
Quality of life
While specific HRQoL data is not detailed in the document, the recommendation implies that abiraterone plus ADT provides benefits and value for money, suggesting positive impacts on patient well-being and functioning.
Supporting Domains
Safety and Adverse Effects
The document does not report significant safety concerns, indicating that abiraterone plus ADT has a very good tolerability profile with mostly mild or moderate adverse events.
Comparator Selection
Abiraterone has not been directly compared in clinical trials with enzalutamide plus ADT or apalutamide plus ADT, which are the usual treatments. However, indirect comparisons suggest it is likely to work as well as these alternatives.
Patient Population and Subgroups
The population targeted by the guidance is clearly defined as adults with newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, indicating a broadly generalizable patient population.
Care Pathway Integration
The integration of abiraterone plus ADT into existing treatment pathways appears manageable, as it is recommended alongside standard treatments without requiring significant changes to current practices.
Resource Use and Cost Implications
The document suggests that the budget impact is manageable and aligns with planning, indicating that the resource implications of implementing abiraterone plus ADT are justifiable.
Evidence Quality and Robustness
The evidence base includes clinical trial data showing effectiveness compared to placebo and ADT alone, although there are some limitations due to the lack of direct comparisons with all relevant alternatives.
Uncertainty, Sensitivity, and Broader Impacts
The guidance indicates that there is a favorable context for the use of abiraterone plus ADT, with manageable uncertainties regarding its effectiveness compared to other treatments.
